Resources

To address the critical challenges of neonatal and maternal mortality, Ghana Health Service and PATH have expanded infectious disease screening and treatment among pregnant women through the Integrated Antenatal Care project (2022‒2024).Working mainly at the primary health care level in nearly 70 facilities across 5 districts of Ghana’s Bono East Region, the project built the capacities of health care providers, improved availability of services through antenatal care, and strengthened linkages between primary and referral facilities.This manual outlines the project's health worker training curriculum to improve the overall quality of care, including diagnosis, prevention, and management of maternal infections in pregnant women.The manual includes six modules: introduction, infection prevention and control, laboratory diagnosis, clinical management of common infections in pregnancy, antimicrobial resistance, and monitoring and evaluation.The training is intended for all health workers providing clinical and public health services at the primary care level, including district hospitals, health centers, clinics, and Community-based Health Planning and Services facilities.

This toolkit highlights how PATH’s Living Labs initiative uses a 4D human centered design approach to engage frontline immunization health care workers to understand factors that affect their motivation and engagement in providing health care services.The tools in this methodology are geared toward co-creating solutions that are in the innovation sweet spot, which is the point at which the three innovation attributes (desirability, feasibility , and viability) overlap. The tools seek to accelerate innovation and foster rapid testing and evaluation.A key aspect is to frame the problem that is, to identify and understand the user, their needs, and their context and then co create solutions that respond to those needs. Although our learned experiences largely involved frontline immunization workers, this toolkit has also been applied with community members, caregivers, community health workers, and ministry of health decision makers, as well as global development stakeholders, to address the system wide complexities of a health challenge.

A synthesis of the full review on current, published evidence relevant to single-dose HPV vaccination. This includes immunogenicity, efficacy and effectiveness; identification of gaps in the evidence; and forthcoming evidence. Visit the Single-Dose HPV Vaccine Evaluation Consortium page for additional resources.

Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced clinical development include injectable next-generation rotavirus vaccines (iNGRVs), which have the potential to better protect children against disease, be combined with existing routine immunizations, and be even more affordable than the current LORVs. PATH conducted a series of studies to understand the real public health value of iNGRVs to help inform decisions by international agencies, funders, vaccine manufacturers, and countries. This included a feasibility and acceptability study with national stakeholders and healthcare providers in Ghana, Kenya, Malawi, Peru, Senegal, and Sri Lanka to assess their preferences for different hypothetical rotavirus vaccine options. These briefs provide an overview of the results in each of the study countries.

Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced clinical development include injectable next-generation rotavirus vaccines (iNGRVs), which have the potential to better protect children against disease, be combined with existing routine immunizations, and be even more affordable than the current LORVs. PATH conducted a series of studies to understand the real public health value of iNGRVs to help inform decisions by international agencies, funders, vaccine manufacturers, and countries. This included: targeted analyses on the ideal age group for iNGRVs and potential future combination vaccine options, impact and cost effectiveness analyses, a feasibility and acceptability study with national stakeholders and healthcare providers in six countries, and a demand forecast. This brief provides a comprehensive summary of the results.